CDRH’s Owen Faris: New Clinical Trials Program Will Speed Up IDE Approvals
This article was originally published in The Gray Sheet
Executive Summary
In an interview with “The Gray Sheet,” CDRH’s Acting Clinical Trials Director Owen Faris discusses the device center’s new pre-market clinical trials program aimed at speeding up approval times for investigational device exemptions and increasing the number of IDE trials in the U.S.
You may also be interested in...
FDA To Consider Patient Input For Benefit-Risk Decisions For IDEs
The agency will take into account patient preferences when making benefit-risk determinations for investigational device exemptions, according to a June 18 draft guidance.
CDRH Touts Progress On Clinical Study Reviews
The device center says that the number of review cycles and the median review time for investigational device exemptions dropped ahead of expectations during the past year. Aggressive goals remain for 2015.
Editors' Picks: Six Themes From 2014
Industry closely scrutinized FDA's premarket review performance as the agency took steps to streamline reviews and remake the U.S. postmarket surveillance system. Meanwhile: device mega-mergers accelerated; one of the most hotly anticipated medtech innovations faltered; and national elections swept in Republican control of Congress. Here is a look back at coverage and analysis from "The Gray Sheet" on six key themes for the medical device and diagnostics industry in 2014.